Roche RHHBY announced positive top-line data from a late-stage study of its marketed drug, Gazyva/Gazyvaro (obinutuzumab), to ...

After collecting a handful of oncology approvals since its first leukemia nod in 2013, Roche’s Biogen-partnered Rituxan ...

Positive topline results were announced from a phase 3 study of obinutuzumab in patients with lupus nephritis.

In the Phase III REGENCY study, Gazyva elicited superior complete renal response rates in patients with lupus nephritis ...

Genentech announced positive results from the Phase III study (REGENCY) of Gazyva (Obinutuzumab) for people with active lupus nephritis (LN).

Swiss pharma giant Roche has announced positive top-line results from the Phase III REGENCY study of Gazyva/Gazyvaro ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the Phase ...

Roche (RHHBY) announced that the phase III REGENCY study of Gazyva/Gazyvaro (obinutuzumab) in patients with active lupus nephritis ...

Roche has announced positive results from its phase III REGENCY study, showing that its drug Gazyva®/Gazyvaro® (obinutuzumab) ...

Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus ...

The REGENCY study met its primary endpoint, demonstrating statistically significant and clinically meaningful treatment benefits in people with active lupus nephritis – – Gazyva is designed to ...